BCL2 and hematologic disorder: Venetoclax is a selective B-cell lymphoma 2 (BCL-2) inhibitor currently used as monotherapy or in combination with other agents in a wide range of hematologic malignancies, including CLL, myelodysplastic syndrome, and acute myeloid leukemia [16,17,18].